Federal Register of Legislation - Australian Government

Primary content

PB 88 of 2020 Determinations/Health as made
This instrument amends the National Health (Weighted average disclosed price – October 2020 reduction day) Determination 2020 (PB 54 of 2020) to amend the approved ex-manufacturer prices of certain brands to reflect changes that have resulted from the Price Disclosure dispute resolution process for the 2020 October cycle.
Administered by: Health
Registered 11 Sep 2020

 

PB 88 of 2020

National Health (Weighted average disclosed price – October 2020 reduction day) Amendment Determination 2020

National Health Act 1953

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Department of Health, delegate of the Minister for Health, make this determination under subsection 99ADB(4) of the National Health Act 1953.

Dated:  9 September 2020

 

 

 

 

 

 

 

 

 

THEA CONNOLLY

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 


1              Name of Instrument

       (1)     This instrument is the National Health (Weighted average disclosed price – October 2020 reduction day) Amendment Determination 2020.

       (2)     This instrument may also be cited as PB 88 of 2020.

2              Commencement

                This instrument commences on the day after it is registered.

3                   Amendments to PB 54 of 2020

Schedule 1 amends the National Health (Weighted average disclosed price – October 2020 reduction day) Determination 2020 (PB 54 of 2020).

 

 


Schedule 1     Amendments

 

[1]     Schedule 1

after:

77

Entecavir

Tablet 1 mg (as monohydrate)

Oral

ENTECLUDE

117.91

 

omit:

78

Epirubicin

Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL

Injection/intravesical

Epirubicin ACT

25.49

79

Epirubicin

Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL

Injection/intravesical

Epirube

50.98

80

Epirubicin

Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL

Injection/intravesical

Epirubicin Accord

50.98

81

Epirubicin

Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL

Injection/intravesical

Epirubicin ACT

50.98

82

Epirubicin

Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL

Injection/intravesical

Epirube

12.75

83

Epirubicin

Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL

Injection/intravesical

Epirubicin ACT

12.75

84

Etoposide

Powder for I.V. infusion 1 g (as phosphate)

Injection

Etopophos

342.38

85

Etoposide

Solution for I.V. infusion 100 mg in 5 mL

Injection

Etoposide Ebewe

34.24

86

Etoposide

Solution for I.V. infusion 100 mg in 5 mL

Injection

Pfizer Australia Pty Ltd

34.24

 

[2]     Schedule 1

after:

228

Zoledronic acid

Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL

Injection

DBL Zoledronic Acid

72.79

 

omit:

229

Zoledronic acid

Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL

Injection

Aclasta

97.45

230

Zoledronic acid

Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL

Injection

Osteovan

97.45

231

Zoledronic acid

Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL

Injection

Ostira

97.45

232

Zoledronic acid

Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL

Injection

Zoledasta

97.45


substitute:

 

229

Zoledronic acid

Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL

Injection

Aclasta

97.47

230

Zoledronic acid

Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL

Injection

Osteovan

97.47

231

Zoledronic acid

Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL

Injection

Ostira

97.47

232

Zoledronic acid

Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL

Injection

Zoledasta

97.47

 

 

Schedule 2     Amendments

 

[3]     Schedule 2

after:

1,024

Enoxaparin

Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe

Injection

Enoxaparin Winthrop

54.37

 

insert:

1,024A

Epirubicin

Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL

Injection/intravesical

Epirubicin ACT

25.49

1,024B

Epirubicin

Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL

Injection/intravesical

Epirube

50.98

1,024C

Epirubicin

Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL

Injection/intravesical

Epirubicin Accord

50.98

1,024D

Epirubicin

Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL

Injection/intravesical

Epirubicin ACT

50.98

1,024E

Epirubicin

Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL

Injection/intravesical

Epirube

12.75

1,024F

Epirubicin

Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL

Injection/intravesical

Epirubicin ACT

12.75


[4]     Schedule 2

after:

1,125

Etoposide

Capsule 50 mg

Oral

Vepesid

391.11

 

insert:

1,125A

Etoposide

Powder for I.V. infusion 1 g (as phosphate)

Injection

Etopophos

342.38

1,125B

Etoposide

Solution for I.V. infusion 100 mg in 5 mL

Injection

Etoposide Ebewe

34.24

1,125C

Etoposide

Solution for I.V. infusion 100 mg in 5 mL

Injection

Pfizer Australia Pty Ltd

34.24

 

 

 [5]    Schedule 2

after:

1,594

Imipramine

Tablet containing imipramine hydrochloride 25 mg

Oral

Tofranil 25

7.11

 

insert:

1,594A

Imipramine

Tablet containing imipramine hydrochloride 25 mg USP

Oral

Imipramine (Leading)

19.00

 


 

[6]     Schedule 2

after:

1,902

Levodopa with carbidopa

Tablet 250 mg-25 mg (USP)

Oral

Carbidopa and Levodopa Tablets, USP

44.63

 

insert:

1,902A

Levodopa with carbidopa and entacapone

Tablet 100 mg-25 mg (as monohydrate)-200 mg

Oral

Lecteva

110.74

1,902B

Levodopa with carbidopa and entacapone

Tablet 100 mg-25 mg (as monohydrate)-200 mg

Oral

Carlevent

110.74

1,902C

Levodopa with carbidopa and entacapone

Tablet 100 mg-25 mg (as monohydrate)-200 mg

Oral

Stalevo 100/25/200mg

110.74

1,902D

Levodopa with carbidopa and entacapone

Tablet 150 mg-37.5 mg (as monohydrate)-200 mg

Oral

Lecteva

121.22

1,902E

Levodopa with carbidopa and entacapone

Tablet 150 mg-37.5 mg (as monohydrate)-200 mg

Oral

Carlevent

121.22

1,902F

Levodopa with carbidopa and entacapone

Tablet 150 mg-37.5 mg (as monohydrate)-200 mg

Oral

Stalevo 150/37.5/200mg

121.22

1,902G

Levodopa with carbidopa and entacapone

Tablet 50 mg-12.5 mg (as monohydrate)-200 mg

Oral

Carlevent

100.26

1,902H

Levodopa with carbidopa and entacapone

Tablet 50 mg-12.5 mg (as monohydrate)-200 mg

Oral

Lecteva

100.26

1,902I

Levodopa with carbidopa and entacapone

Tablet 50 mg-12.5 mg (as monohydrate)-200 mg

Oral

Stalevo 50/12.5/200mg

100.26

1,902J

Levodopa with carbidopa and entacapone

Tablet 125 mg-31.25 mg (as monohydrate)-200 mg

Oral

Lecteva

114.94

1,902K

Levodopa with carbidopa and entacapone

Tablet 125 mg-31.25 mg (as monohydrate)-200 mg

Oral

Stalevo 125/31.25/200mg

114.94

1,902L

Levodopa with carbidopa and entacapone

Tablet 125 mg-31.25 mg (as monohydrate)-200 mg

Oral

Carlevent

114.94

1,902M

Levodopa with carbidopa and entacapone

Tablet 200 mg-50 mg (as monohydrate)-200 mg

Oral

Carlevent

130.86

1,902N

Levodopa with carbidopa and entacapone

Tablet 200 mg-50 mg (as monohydrate)-200 mg

Oral

Stalevo 200/50/200mg

130.86

1,902O

Levodopa with carbidopa and entacapone

Tablet 200 mg-50 mg (as monohydrate)-200 mg

Oral

Lecteva

130.86

1,902P

Levodopa with carbidopa and entacapone

Tablet 75 mg-18.75 mg (as monohydrate)-200 mg

Oral

Lecteva

104.87

1,902Q

Levodopa with carbidopa and entacapone

Tablet 75 mg-18.75 mg (as monohydrate)-200 mg

Oral

Carlevent

104.87

1,902R

Levodopa with carbidopa and entacapone

Tablet 75 mg-18.75 mg (as monohydrate)-200 mg

Oral

Stalevo 75/18.75/200mg

104.87

 

[7]     Schedule 2

after:

1,954

Losartan

Tablet containing losartan potassium 50 mg

Oral

Cozavan

7.25

 

insert:

1,954A

Lurasidone

Tablet containing lurasidone hydrochloride 40 mg

Oral

Lurasidone Lupin

46.48

1,954B

Lurasidone

Tablet containing lurasidone hydrochloride 40 mg

Oral

Ardix Lurasidone

46.48

1,954C

Lurasidone

Tablet containing lurasidone hydrochloride 40 mg

Oral

Latuda

46.48

1,954D

Lurasidone

Tablet containing lurasidone hydrochloride 80 mg

Oral

Latuda

92.96

1,954E

Lurasidone

Tablet containing lurasidone hydrochloride 80 mg

Oral

Ardix Lurasidone

92.96

1,954F

Lurasidone

Tablet containing lurasidone hydrochloride 80 mg

Oral

Lurasidone Lupin

92.96

 

[8]     Schedule 2

after:

2,035

Metformin

Tablet (extended release) containing metformin hydrochloride 500 mg

Oral

Metformin XR 500 APOTEX

3.72

 

insert:

2.035A

Metformin

Tablet (prolonged release) containing metformin hydrochloride 500 mg

Oral

Metformin (Medsurge)

4.01

 

 

[9]     Schedule 2

after:

2,096

Methylphenidate

Capsule containing methylphenidate hydrochloride 40 mg (modified release)

Oral

Ritalin LA

38.07

 

insert:

2,096A

Methylphenidate

Capsule containing methylphenidate hydrochloride 60 mg (modified release)

Oral

Ritalin LA

51.01

 

 

[10]   Schedule 2

after:

2,367

Nitrazepam

Tablet 5 mg

Oral

Mogadon

1.48

 

insert:

2,367A

Nitrofurantoin

Capsule 100 mg

Oral

APO-Nitrofurantoin

14.67

2,367B

Nitrofurantoin

Capsule 100 mg

Oral

Macrodantin

14.67

2,367C

Nitrofurantoin

Capsule 50 mg

Oral

Macrodantin

10.46

2,367D

Nitrofurantoin

Capsule 50 mg

Oral

APO-Nitrofurantoin

10.46

 

 


 

[11]   Schedule 2

after:

3,224

Salbutamol

Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)

Inhalation by mouth

Ventolin CFC-free

3.88

 

insert:

3,224A

Salbutamol

Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)

Inhalation by Mouth

Zempreon CFC-Free with dose counter

4.49

3,224B

Salbutamol

Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)

Inhalation by Mouth

Ventolin CFC-Free with dose counter

4.49